Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - October 2012

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Ambrisentan
Amlodipine and Benazepril
Atorvastatin
Azilsartan medoxomil
Azilsartan Medoxomil and Chlorthalidone
Bevacizumab
Bortezomib
Bosentan
Canakinumab
Certolizumab
Clomiphene
Clomipramine
Duloxetine
Entecavir
Esomeprazole
Everolimus
Ezetimibe and simvastatin
Fenofibric Acid
Fluvastatin
Imipramine
Ipilimumab
Irbesartan and Hydrochlorothiazide
Lovastatin
Meclizine
Milnacipran Hcl
Mirtazapine
Naproxen and Esomeprazole Magnesium
Niacin Extended Release and Lovastatin
Nortriptyline
Omeprazole
Oxybutynin Hydrochloride
Pamidronate
Pantoprazole
Pemetrexed
Pitavastatin
Pravastatin
Rabeprazole
Rituximab
Rosuvastatin
Simvastatin
Simvastatin and Sitagliptin
Sitagliptin
Sitagliptin-Metformin
Telmisartan
Telmisartan and Amlodipine
Tocilizumab Injection
Topiramate
Valsartan
Valsartan and Hydrochlorothiazide
Vandetanib

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Get Health and Wellness Secrets from Our Engaging eBooks
Stay Connected
Available on the Android Market Available on the App Store